FDA Grants Breakthrough Therapy Status to Daridorexant for Children's Insomnia in a First for the Field

ALLSCHWIL, Switzerland — The United States Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to daridorexant for the treatment of insomnia disorder in children and adolescents aged 10 to under 18, Swiss drugmaker Idorsia announced on 4 November 2026. The decision marks a significant regulatory step for a condition that, according to Idorsia, currently has no FDA-approved pharmacological treatment in children and adolescents — and it follows a Phase 2 trial in which a single 50 mg dose increased objectively measured sleep by 50 minutes overall, and by 64 minutes in young people with neurodevelopmental disorders.

Breakthrough Therapy Designation is not an approval. It is a programme intended to expedite the development and review of drugs for serious conditions where preliminary clinical evidence suggests a substantial improvement over available therapies, and it brings intensive FDA guidance and closer collaboration on the development programme. For families, the practical meaning is narrower but still important: the regulator has recognised both the unmet need in paediatric insomnia and the strength of the early evidence, and Idorsia says it now expects to start a Phase 3 programme in the second half of 2027.

Illustration: A teenager sleeps peacefully at night, while a parent reads quietly nearby.

What Happened

Idorsia, headquartered in Allschwil near Basel, said on 4 November 2026 that the FDA had granted the designation for daridorexant in insomnia disorder in patients aged 10 to under 18. The company said the designation recognises the clinical evidence supporting daridorexant and the significant unmet medical need in paediatric insomnia, where no pharmacological treatment is currently approved by the FDA. It added that the designation enables intensive FDA guidance and more frequent interactions on an efficient development programme.

Daridorexant is a dual orexin receptor antagonist, often shortened to DORA. Rather than broadly suppressing brain activity in the way traditional sleeping medicines do, it selectively reduces wake drive by targeting the orexin system, which helps regulate wakefulness. Idorsia says the drug was designed with a pharmacokinetic profile intended to provide efficacy through the night while minimising residual exposure the following morning — a feature the company argues is particularly relevant for children and adolescents, for whom next-day grogginess and daytime functioning matter as much as falling asleep.

The drug is already marketed for adults under the brand name Quviviq in North America and Europe, and is available in key Asia-Pacific and Middle East markets through commercial partnerships. In the European Union, it is authorised for adults with insomnia lasting at least three months, at doses of 50 mg or 25 mg. For children and adolescents, however, Idorsia stresses in every announcement that daridorexant is investigational and is not approved or marketed in any country. That distinction matters: the new designation changes how the drug is developed with the regulator, not what doctors can prescribe today.

Idorsia's chief medical officer, Dr Amer Joseph, said the designation underscored both the unmet need and the encouraging evidence so far. He pointed to the drug's profile — largely cleared by the next morning, with no accumulation on repeated dosing in the company's account — as what allowed the paediatric trial to test multiple doses, including the highest approved adult dose of 50 mg. At that dose, he said, daridorexant demonstrated robust efficacy while maintaining a favourable tolerability profile, which he called an especially important consideration in children and adolescents. The company said it looks forward to working closely with the FDA as it prepares the Phase 3 programme and generates the evidence needed to bring what could become the first FDA-approved pharmacological treatment for paediatric insomnia to patients and their families.

Background

Paediatric insomnia is characterised, in Idorsia's description, by difficulty initiating or maintaining sleep that is perceived as a problem by the child or caregiver because of its severity, chronicity and frequency, and the significant daytime impairment it causes for the child and family. The company puts the prevalence of the disorder at roughly 8 to 12 per cent, rising from childhood into adolescence. Its burden is particularly high in young people with neurodevelopmental disorders, including autism spectrum disorder and attention-deficit/hyperactivity disorder (ADHD). Insufficient or disrupted sleep can affect attention, learning, emotional regulation, behaviour and quality of life, while worsening the symptoms and comorbidities associated with neurodevelopmental disorders.

That burden is part of why the field has watched this programme closely. Sleep problems in children are usually managed first with behavioural approaches — consistent routines, sleep hygiene and, where available, behavioural sleep interventions. When those are not enough, clinicians have historically had to rely on medicines approved for other conditions or for adults, used off-label, because no drug has been approved specifically for insomnia in children. A dedicated, evidence-based option would therefore fill a gap that paediatric sleep specialists have described for years, although any such option still has to clear the much higher bar of a full Phase 3 programme and a formal approval decision.

The evidence behind the new designation comes from a single Phase 2 dose-finding study, registered as NCT05423717, whose results Idorsia presented at Sleep Europe 2026 on 23 October 2026. The multicentre, randomised, double-blind, placebo-controlled trial evaluated daridorexant at 10 mg, 25 mg and 50 mg, or placebo, over two weeks in 165 children and adolescents aged 10 to under 18 with insomnia disorder diagnosed under DSM-5 criteria. Participants were randomised in a 1:1:1:1 ratio. The study included young people without neurodevelopmental disorders, those with subthreshold autism or ADHD traits, and those with diagnosed neurodevelopmental disorders — a deliberately broad mix that mirrors the real population who might one day use the treatment.

The primary objective was to characterise the dose-response relationship on objective total sleep time, measured by polysomnography — the overnight sleep-laboratory recording that tracks brain waves, breathing, movement and other signals, rather than relying only on sleep diaries or questionnaires. The primary endpoint was the change from baseline to Day 1 in total sleep time measured by polysomnography. Additional assessments covered objective and subjective sleep measures, sleep quality, morning sleepiness and alertness, daytime functioning, pharmacokinetics, and safety and tolerability.

Illustration: A sleep laboratory monitors a young patient overnight with polysomnography.

The study met its primary endpoint, Idorsia reported, demonstrating a statistically significant dose-response in objectively measured total sleep time after the first dose, with a p-value of 0.0185 for the dose-dependent improvement from baseline on Day 1. A single 50 mg dose increased objective total sleep time by 50 minutes from baseline, compared with 20 minutes on placebo, on a least-square mean basis. In children and adolescents with neurodevelopmental disorders, the 50 mg dose increased total sleep time by 64 minutes from baseline, compared with 27 minutes on placebo. The company also reported a numerical decrease in morning sleepiness at the higher dose, and dose-dependent improvements across additional objective and subjective sleep parameters.

On safety, Idorsia said the study confirmed the drug's safety and tolerability profile for the first time in paediatric patients as young as ten. Even at 50 mg — the recommended adult dose — the safety profile remained similar to placebo, the company said, with no adverse events denoting drug abuse during treatment and no indication of withdrawal symptoms when treatment stopped. That safety claim is important, but it also carries a clear limit: the trial lasted only two weeks, and a two-week study cannot answer questions about long-term use, growth, development or school performance. Those questions are precisely what a Phase 3 programme is designed to address, and they are why regulators, clinicians and families should treat the current results as promising early evidence rather than a conclusion.

There is one small numerical discrepancy worth noting for transparency. Idorsia reports 165 participants in its announcements, while the ClinicalTrials.gov record for NCT05423717 lists actual enrolment of 166. The difference of one participant does not change the reported findings, but this article follows Idorsia's figure, as the company is the source of the efficacy results, and notes the registry figure here so readers are not misled. The full dataset manuscript is currently under evaluation with a journal, Idorsia said, so independent peer review of the complete results is still pending.

Why It Matters

The designation matters for three reasons. First, it is a formal regulatory signal. Breakthrough Therapy Designation is granted on preliminary evidence that a drug may offer a substantial improvement on a clinically significant endpoint, together with available safety data. It does not guarantee approval, but it does mean the FDA will work more closely with the sponsor, offering intensive guidance intended to make development and review as efficient as possible. For a field with no approved pharmacological option at all, that closer collaboration can shorten the path to a definitive answer — in either direction.

Second, the trial design itself is a step forward for paediatric sleep research. It is, according to Idorsia, the first and only Phase 2 study of a dual orexin receptor antagonist in children with insomnia disorder, and the first controlled study of the class in this population. Using polysomnography as the primary measure, rather than subjective reports alone, gives the headline sleep-time gains an objective anchor. The inclusion of young people with neurodevelopmental disorders — who carry the heaviest sleep burden and are often excluded from trials — also makes the results more relevant to the children most in need of help, and the larger gains in that subgroup, 64 minutes against 27 minutes on placebo, are the finding most likely to shape the Phase 3 design.

Third, the mechanism may matter for daytime life, not just for the night. Traditional hypnotics can leave next-day drowsiness, and some carry risks of dependence and withdrawal. Daridorexant's orexin-targeted approach is designed to quiet an overactive wake signal rather than sedate the brain broadly, and adult trials published in The Lancet Neurology showed improvements in sleep onset, sleep maintenance and self-reported total sleep time at 25 mg and 50 mg, with the 50 mg dose also improving daytime functioning. If a similar daytime benefit is confirmed in children — and that is still an open question, not a finding of the two-week trial — it could matter for attention, learning and family life in ways that a few extra minutes of sleep alone would not capture.

At the same time, the limits deserve equal emphasis. A 50-minute gain after a single dose, measured in a sleep laboratory, is not the same as sustained, real-world improvement over months. The trial was short, the full data have not yet been peer-reviewed, and the drug remains unapproved for children everywhere. Parents should not seek out daridorexant for a child on the basis of this announcement, and clinicians cannot prescribe it for paediatric insomnia today. This article is general information only and is not medical advice; families concerned about a child's sleep should speak to their own clinician about behavioural and other established approaches.

Illustration: A doctor and a researcher review a medicine dossier as a regulatory breakthrough brings closer scrutiny.

What Happens Next

Idorsia says it is consolidating supportive comments from global health authorities on the protocol for the paediatric Phase 3 clinical development programme, and expects to initiate the new programme in the second half of 2027. The Phase 3 programme will need to confirm efficacy over longer treatment periods, in larger and more diverse groups of children, and to build a fuller safety picture — including effects on daytime functioning, mood, behaviour and development — before any approval application can succeed.

Several milestones will tell observers whether the programme is on track. The first is the peer-reviewed publication of the full Phase 2 dataset, which will allow independent researchers to scrutinise the results beyond the company's summary, including the secondary endpoints and the safety data in detail. The second is the announcement of the Phase 3 design itself: its size, duration, age groups, endpoints and whether it includes the neurodevelopmental-disorder subgroup that showed the largest gains. The third is the start of enrolment in the second half of 2027, which Idorsia has now put on the record as its target. Any delay to that timetable, or any change in the design, will be a signal in itself.

Beyond Idorsia, the designation may also encourage wider investment in paediatric sleep. If a major regulator is willing to expedite a dedicated paediatric insomnia programme, other developers may see a clearer path for their own candidates, and health systems may pay closer attention to sleep as a treatable contributor to children's learning, behaviour and wellbeing. But that wider effect depends on the Phase 3 results. A breakthrough designation is a door opening, not a destination reached — and the children and families waiting for a safe, approved option will judge this programme by the evidence it produces next, not by the announcement it made today.

Sponsored: explore today's featured sponsored offers

FAQ

What is daridorexant?

Daridorexant is a dual orexin receptor antagonist developed by Idorsia and sold for adults as Quviviq. It works by selectively reducing wake drive through the orexin system, rather than broadly suppressing brain activity like traditional sleeping medicines.

Has the FDA approved daridorexant for children?

No. The FDA has granted Breakthrough Therapy Designation for insomnia disorder in patients aged 10 to under 18, which expedites development and review. Paediatric use remains investigational and is not approved or marketed for children or adolescents in any country.

How much extra sleep did the Phase 2 trial show?

A single 50 mg dose increased objectively measured total sleep time by 50 minutes from baseline, compared with 20 minutes on placebo. In participants with neurodevelopmental disorders, the gain was 64 minutes, compared with 27 minutes on placebo. These are least-square mean figures from a two-week, 165-participant trial.

When could a paediatric treatment become available?

Not before a Phase 3 programme is completed and an approval application is reviewed. Idorsia expects to start its Phase 3 programme in the second half of 2027, so any approval would still be years away, and is not guaranteed.

What should families do about a child's sleep problems now?

Speak to the child's own clinician. Established care typically starts with behavioural approaches such as consistent routines and sleep hygiene, and any medicine decision for a child should be made with a clinician who knows the child's history — not on the basis of a trial announcement.

Sources

• Idorsia Ltd, "Breakthrough Therapy Designation granted by the FDA for daridorexant in pediatric insomnia disorder," GlobeNewswire, 4 November 2026 (via Morningstar).
• Idorsia Ltd, "Idorsia presents outstanding results with daridorexant in children and adolescents with insomnia and an expanding body of evidence in adults at Sleep Europe 2026," GlobeNewswire, 23 October 2026.
• Psychiatric Times, "Daridorexant Shows Positive Results in Pediatric Insomnia," October 2026, reporting the Phase 2 trial and Phase 3 plans.
• ClinicalTrials.gov, NCT05423717, dose-finding study of daridorexant in subjects aged 10 to under 18 years with insomnia disorder.